Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We are maintaining our Neutral rating on Symmetry Medical (SMA - Analyst Report) following its mixed first-quarter fiscal 2011 results.

Earnings for the quarter missed the Zacks Consensus Estimate by a penny while profit dropped 13% year over year on account of facility consolidation and management transition charges, as well as employee severance payments.

On a positive note, revenues for the instrument supplier to orthopedic device makers jumped roughly 13% year over year in the quarter, beating the Zacks Consensus Estimate. Sales were boosted by higher customer shipments across the Indiana-based company’s instruments and surgical cases businesses. Healthy double-digit growth in surgical instruments and cases revenues were, in part, masked by a decline in the orthopedic implants business.

Charges associated with facility consolidation, management transition and severance payments led a decline in operating margin in the quarter. The company reaffirmed its revenues and earnings guidance for fiscal 2011.

Symmetry is the largest OEM provider of orthopedic implants and instruments to orthopedic device manufacturers. Its major customers include Johnson & Johnson’s (JNJ - Analyst Report) DePuy, Stryker (SYK - Analyst Report) and Zimmer Holdings (ZMH - Analyst Report).

The company has created a distinct competitive niche in the orthopedic devices market with its “Total Solutions Approach”, providing a substantial growth opportunity. Most of its customers are expanding outsourcing, realizing the benefits of a “One-stop shop” solution that allows them to focus their efforts on marketing and R&D.

Symmetry has adopted a three-pronged strategy to tackle economic challenges by preserving cash, developing an extensive supply chain and focusing on bottom line improvement. Moreover, the company has diversified its offerings into areas outside of orthopedics, such as dental, osteobiologic and endoscopy.

Symmetry is investing in revamping its management structure and enhancing customer collaboration, which should push growth moving forward. The company should benefit from higher demand for its solutions as its major customers ramp up spending and accelerate product launches.

However, Symmetry still faces price and procedure volume headwinds in the orthopedic space. Also, the company’s high spending may continue to weigh on its bottom line. Our recommendation on the stock is in agreement with the short-term Zacks #3 Rank (Hold).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%